J&J Building Portfolio for CTC and Companion Diagnostics

In recent interviews, J&J officials spoke about ongoing work to further develop its technology for circulating tumor cells to include characterization capabilities, and its new center of excellence for companion diagnostics to leverage partnerships with other diagnostic firms.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories